



You may be eligible for this trial



Get started

## You are not out of options

Learn more about a clinical trial for men with metastatic castrate-resistant prostate cancer

Get started

### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).

Decline All

Accept All

Cookies Preferences

The MEVPRO-1 clinical trial is for men who have metastatic prostate cancer not responding to hormone therapy (including Zytiga®).

The purpose of MEVPRO-1 is to see if taking the study medicine (mevrometostat) alongside a standard treatment (enzalutamide) is safe and works to slow down or stop the growth of prostate cancer compared with standard treatment alone.

You may be eligible for this trial

Get started

Watch a short video about the study medicine



### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).

## About

The study medicine is called mevrometostat. You will take it once a day.

Prostate cancer cells need hormones (such as testosterone) to grow and divide and can often become resistant to hormone therapy and continue to progress and spread to other parts of the body.

You may be eligible for this trial

Get started

cancer to progress.

Mevrometostat, the study medicine, is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.

# Who may participate



The MEVPRO-1 clinical trial may be an option for adults with metastatic castrate-resistant prostate cancer that has become resistant to hormone therapy. Specifically, participants must have previously been treated with abiraterone acetate (Zytiga®) for a

Participants can have received chemotherapy since their cancer

Condition

Metastatic Prostate C

Age

## We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).

18+ years

You may be eligible for this trial

Get started

Male

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

[View more eligibility criteria](#) >



## Get started – See if you may be eligible

### Answer a 2-minute questionnaire

A first step as you consider this trial is to answer a 2-minute questionnaire about your health and medical history. If you are a good fit for you, you may choose to speak with a study representative or Pfizer Clinical Trial Contact Center.

### Speak with a study representative

If you're interested, a Pfizer Clinical Trial Contact Center representative will do a more detailed review of the trial and determine if you may be able to participate and be reimbursed for your travel.

### Confirm your eligibility.

### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).

Your answers to these questions will only be linked to you if your responses indicate that you may be eligible to participate in this study and you choose to share your contact information with the study team. Pfizer study team members

You may be eligible for this trial

Get started

Answer a 2-minute questionnaire

If you would like to proceed with taking the questionnaire, you may click 'next'.

☐ Next

Continue →

## What to expect



Participants will be assigned to one of two groups:

- Study medicine (mevpro)

**OR**

- Enzalutamide **OR** docetaxel (de

### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).

Mevrometostat is taken as tablets by mouth twice-a-day and enzalutamide is taken as capsules by mouth once-a-day.

You may be eligible for this trial

Get started

### Length of study treatment



Depends on how the cancer responds and how well the study medicine is tolerated

### Number of study visits



3 or 4 in the first 2 months, then every 3 or 4 weeks

### Long-term follow up

Every 12 weeks

#### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).

### Frequently asked questions

## How long do study visits last?



You may be eligible for this trial

Get started

cancer worsens, they have any side effects that become too severe, they or their doctor decide they should stop, or the trial ends. Participants receiving docetaxel may be treated for up to 30 weeks.

Is this helpful?

## What are the possible benefits of participating?



## What are the possible risks of participating?

### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).



## Discover local

 **Discover**

You may be eligible for this trial


Get started



**How clinical trials  
work**



**Protecting your  
safety & privacy**



**Steps to join  
clinical trial**



**About Pfizer**

**For investigators**

**The Breakthrough news**

**Site map**

**Terms of use**

**We Care About Your Privacy**

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).



[Privacy policy](#)[Contact us](#)

---

You may be eligible for this trial

[Get started](#)

### We Care About Your Privacy

Pfizer uses cookies and similar technologies to enhance and personalize your customer experience. By granting us permission, you enable Pfizer and our analytics and marketing partners to collect, use, and share information about your website interactions to tailor your digital experiences, our services, and content for you. To learn more about how Pfizer uses these technologies, please read our [Privacy Policy](#).